Literature DB >> 9024664

CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia.

J He1, Y Chen, M Farzan, H Choe, A Ohagen, S Gartner, J Busciglio, X Yang, W Hofmann, W Newman, C R Mackay, J Sodroski, D Gabuzda.   

Abstract

Several members of the chemokine receptor family are used together with CD4 for HIV-1 entry into target cells. T cell line-tropic (T-tropic) HIV-1 viruses use the chemokine receptor CXCR4 as a co-receptor, whereas macrophage-tropic (M-tropic) primary viruses use CCR5 (refs 2-6). Individuals with defective CCR5 alleles exhibit resistance to HIV-1 infection, suggesting that CCR5 has an important role in vivo in HIV-1 replication. A subset of primary viruses can use CCR3 as well as CCR5 as a co-receptor, but the in vivo contribution of CCR3 to HIV-1 infection and pathogenesis is unknown. HIV-1 infects the central nervous system (CNS) and causes the dementia associated with AIDS. Here we report that the major target cells for HIV-1 infection in the CNS, the microglia, express both CCR3 and CCR5. The CCR3 ligand, eotaxin, and an anti-CCR3 antibody inhibited HIV-1 infection of microglia, as did MIP-1beta, which is a CCR5 ligand. Our results suggest that both CCR3 and CCR5 promote efficient infection of the CNS by HIV-1.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9024664     DOI: 10.1038/385645a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  323 in total

1.  Spontaneous and antigen-induced production of HIV-inhibitory beta-chemokines are associated with AIDS-free status.

Authors:  A Garzino-Demo; R B Moss; J B Margolick; F Cleghorn; A Sill; W A Blattner; F Cocchi; D J Carlo; A L DeVico; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

2.  Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies.

Authors:  T W Chun; J S Justement; S Moir; C W Hallahan; L A Ehler; S Liu; M McLaughlin; M Dybul; J M Mican; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

3.  Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry?

Authors:  Y J Zhang; J P Moore
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

Review 4.  Eotaxin and asthma: some answers, more questions.

Authors:  C J Corrigan
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

Review 5.  Chemokines and central nervous system disorders.

Authors:  W J Karpus
Journal:  J Neurovirol       Date:  2001-12       Impact factor: 2.643

Review 6.  Receptors and entry cofactors for retroviruses include single and multiple transmembrane-spanning proteins as well as newly described glycophosphatidylinositol-anchored and secreted proteins.

Authors:  J Overbaugh; A D Miller; M V Eiden
Journal:  Microbiol Mol Biol Rev       Date:  2001-09       Impact factor: 11.056

7.  CD4/CXCR4-independent infection of human astrocytes by a T-tropic strain of HIV-1.

Authors:  B Schweighardt; J T Shieh; W J Atwood
Journal:  J Neurovirol       Date:  2001-04       Impact factor: 2.643

Review 8.  Virus receptors in the human central nervous system.

Authors:  B Schweighardt; W J Atwood
Journal:  J Neurovirol       Date:  2001-06       Impact factor: 2.643

Review 9.  CXC chemokine receptors in the central nervous system: Role in cerebellar neuromodulation and development.

Authors:  Davide Ragozzino
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

10.  Characterization of rodent models of HIV-gp120 and anti-retroviral-associated neuropathic pain.

Authors:  Victoria C J Wallace; Julie Blackbeard; Andrew R Segerdahl; Fauzia Hasnie; Timothy Pheby; Stephen B McMahon; Andrew S C Rice
Journal:  Brain       Date:  2007-08-30       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.